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INTRODUCTION 
 
The efficiency and safety of targeted alpha therapy 
(TAT) has been shown in a large number of pre-clinical 
studies and has been successfully applied to clinical trials. 
Among the different potential alpha-emitters, Astatine 
211 (At-211) is considered to be one of the most 
promising candidates for targeted alpha therapy. So far, 
At-211 has being used in two clinical trials in the US 1 
and Sweden. It is also the subject of a wide research 
program in Nantes (France). A clinical trial of prostate 
cancer is notably planed in the near future. 
Very few data on the chemistry of Astatine are 
available. On the one hand, Astatine is a rare element and 
it has only short half-life radioactive isotopes. On the 
other hand, it is an “invisible” element: the amount of At–
211 produced allows working at ultra trace concentrations 
(typically 10-11 to 10-15 M) and no spectroscopic 
techniques can be used to estimate astatine characteristics 
at the molecular level. As a result, Astatine chemistry is 
not well understood. These two major points restrain the 
development of efficient labelling protocols and the 
utilization of At–211 for TAT 2. 
By analogy with labelling protocols already 
established with iodide, the studies are focused on 
formation of astatine-carbon bounds. While some 
approaches provide “suitable” in vivo stability to move 
into clinical studies, additional studies still need to be 
conducted to develop improved labelling approaches and 
particularly for systemically administration 2. 
 
DESCRIPTION OF THE ACTUAL WORK 
 
Based on these considerations, a research program 
has started in Nantes in 2005 to explore the basic 
properties of At using a multi-disciplinary chemical 
approach. The objective is to contribute to the 
development of efficient labelling protocols applicable in 
nuclear medicine. The particularity of the project is the 
elaboration of a combined experimental and theoretical 
approach to study astatine behaviour in order to access 
both at macroscopic and molecular level data 3-5. 
The theoretical approach is based on quasi-relativistic 
quantum chemistry calculations. The experimental 
approach considers that a given astatine species is 
characterized by its distribution coefficient 
experimentally determined in liquid-liquid or solid-liquid 
biphasic systems. The change in speciation arising from a 
change in experimental conditions is observed by a 
change in the distribution coefficient.  
The existence of an astatine species is validated when 
the thermodynamics parameters obtained by both 
approaches are in agreement. 
 
RESULTS 
 
The methodology enabled us to define a reliable 
Pourbaix diagram (Eh/pH diagram) of astatine in non-
complexing aqueous medium. We showed the existence 
of two stable metallic forms of Astatine, i.e. At+ and AtO+ 
1,3. This highlighted the metallic character of At by 
comparison with others halogens, as it was already 
proposed in the 60’s 6. 
However, no ligand has been so far designed for TAT 
using AtO+ species. Only few data are available regarding 
to its reactivity 7 (what are the atoms interacting with 
AtO+? What is the nature of the bonds formed?). Our 
recent results on the reactivity of AtO+ for model organic 
and inorganic ligands demonstrate the potentiality to form 
both coordination and covalent bonds. These significant 
progress findings offer new perspectives for TAT 
compared to conventional labelling protocols using the 
“halogen character” of At. 
 
REFERENCES  
 
1.  M. R. Zalutsky, D. A. Reardon, G. Akabani, R. E. 
Coleman, A. H. Friedman, H. S. Friedman, R. E. 
McLendon, T. Z. Wong, D. D. Bigner, J. Nucl. Med., 49, 
30 (2008) 
2.  G. Vaidyanathan; M.R. Zalutsky Current 
Radiopharmaceuticals, 1, 177 (2008). 
3.  J. Champion, Exploration du caractère métallique de 
l’astate en milieu aqueux; thesis at Université de Nantes 
(2009). 
4.  J. Champion, C Alliot, S Huclier, D Deniaud, Z Asfari 
and G Montavon Inorganica Chimica Acta, 362, 2654 
(2009) 
5.  J. Champion C. Alliot, E. Renault, B.M. Mokili, M. 
Chérel, N. Galland and G. Montavon; J. Phys. Chem. A, 
114,, 576 (2010). 
6.  E. H. Appelman, J. Am. Chem. Soc. 83, 805 (1961). 
7.  S. Wilburg Current Radiopharmaceuticals, 1, 177 
(2008). 
 
